CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
CareDx announced a definitive agreement to acquire Naveris for $160 million in upfront cash, plus up to $100 million in revenue milestones. Naveris is a commercial-stage precision oncology diagnostics company with $34 million in 2025 revenue and a proprietary blood-based test for viral-mediated cancers.
Key figures
- Revenue
- $34 million
- Tam
- $4.5 billion
- Q1 2026 revenue
- $12 million
- Q1 2026 gross margin
- 65%
- Revenue growth forecast
- 30-40% annually for next three years
- Upfront cash consideration
- $160 million
- Potential milestone payments
- $100 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.